Kinneret Livnat Savitzky

Dr. Kinneret Livnat Savitzky is the Director / Chairperson at a variety of biotech entities, and Held director/chairperson positions in a number of companies and organizations including BioLineRx, ILSI, Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), Compugen Ltd., KAHR medical, DreaMed Diabetes, Biomica, Hadasit, FutuRx, and its portfolio companies.

She is also serving as the Chief Executive Officer and Board member of FutuRx, an Israeli biotechnology accelerator established by OrbiMed Israel Partners, Johnson & Johnson Innovation, and Takeda Ventures Inc., with the office of the Israeli Innovation Authority (IIA). Recently Bayer's venture arm LEAPS joined as a partner in FutuRx as well.

Dr. Savitzky holds the titles: Ph.D. with distinction in Human Genetics from Tel Aviv University, a Master’s degree in human genetics from Tel Aviv University, and a B.Sc. in Biology from The Hebrew University of Jerusalem.